CARBOGEN AMCIS SAS opens new manufacturing facility for sterile liquid drugs in France
The new site increases the company's manufacturing capacity for liquid and freeze-dried products for pre-clinical and clinical trials as well as small-scale commercial use
Dishman Carbogen Amcis announced that its subsidiary, CARBOGEN AMCIS SAS has opened a new facility dedicated to sterile liquid drug product manufacturing in Saint-Beauzire, France
The new site, built on newly acquired land located 7 km from an existing CARBOGEN AMCIS site in Riom, increases product development and manufacturing capacity for liquid and freeze-dried products for pre-clinical and clinical trials as well as small-scale commercial use.
A company statement informed, “The facility forms two new fully automated production lines for liquid and freeze-dried drug products, including highly potent compounds and advanced therapies such as antibody-drug conjugates enabling increased customer access. The lines offer a flexible and versatile set-up, which is unique within Europe and comes at a time when securing fill finish capacity can be a challenge for many pharmaceutical companies.”
Pascal Villemagne, CEO of CARBOGEN AMCIS Group, said, “Our new site will enable us to fully synergise our world-class chemistry skills and continue to bring our customers’ science to life, helping us play our part in the roll-out of new and better treatments, which help improve patients’ quality of life or treat otherwise terminal illness.”
The statement added, “The 9,500 sq m facility will be home to approximately 100 employees and create 50 new jobs throughout 2023.”